Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury

European Journal of Pharmacology
H BrunvandK Grong

Abstract

This study examined the effect of carvedilol, a vasodilating beta-adrenoceptor antagonist and antioxidant, on lethal reperfusion injury in feline hearts subjected to 40 min of regional ischemia and 180 min of reperfusion. 30 open chest anaesthetized cats were randomized into three groups. A control (n = 10) was compared with a group given carvedilol before coronary artery occlusions (n = 10) and a group given carvedilol immediately before and during early reperfusion (n = 10). Regional myocardial function was measured by sonomicrometry. Infarct size was determined by staining the left ventricle with triphenyl tetrazolium chloride. Myocardial blood flow was measured by radiolabeled microspheres. Tissue levels of glutathione were measured after reperfusion. Infarct size was significantly reduced compared to control both when carvedilol was given before ischemia (0.2 +/- 0.1 vs. 17.6 +/- 3.6%, P < 0.05). and when given immediately before reperfusion (3.7 +/- 1.3 vs. 17.6 +/- 3.6%, P < 0.05). Regional shortening improved significantly and the incidence of ventricular fibrillation during early reperfusion was reduced in both groups treated with carvedilol compared to control. Oxidized glutathione did not differ between groups in the...Continue Reading

References

Jul 1, 1977·Progress in Cardiovascular Diseases·M A HeymannA M Rudolph
Jan 11, 1992·Journal of Cardiovascular Pharmacology·G Z FeuersteinR R Ruffolo
Jan 11, 1991·Fundamental & Clinical Pharmacology·A J NicholsR R Ruffolo
Mar 1, 1991·Cardiovascular Drugs and Therapy·R Bolli
Sep 1, 1990·Circulation·R Bolli
May 1, 1989·Circulation·R Engler, E Gilpin
Jul 1, 1987·Progress in Cardiovascular Diseases·L C Becker, G Ambrosio
Feb 1, 1987·Journal of Molecular and Cellular Cardiology·K J Kako
Sep 1, 1994·Pflügers Archiv : European journal of physiology·W SchlackV Thämer
Mar 10, 1994·The American Journal of Cardiology·M O JeroudiR Bolli
Dec 16, 1993·The American Journal of Cardiology·K A ReimerV J Richard
Nov 1, 1993·European Heart Journal·R FerrariO Visioli
Feb 1, 1993·Journal of the American College of Cardiology·R A Kloner

❮ Previous
Next ❯

Citations

Dec 31, 1997·The American Journal of Cardiology·G Z FeuersteinR R Ruffolo
Jan 16, 2002·The Annals of Thoracic Surgery·H J GeisslerS J Allen
May 30, 2001·Advanced Drug Delivery Reviews·D MorinJ Tillement
Jun 27, 2007·International Heart Journal·Ayumi YokoyamaKenjiro Kikuchi
Oct 16, 2012·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Carol Chen-ScarabelliTiziano M Scarabelli
Sep 24, 2005·Pacing and Clinical Electrophysiology : PACE·Nabil El-Sherif, Gioia Turitto
May 5, 2001·Expert Opinion on Pharmacotherapy·G Moe
Jan 13, 2015·Journal of Cardiothoracic and Vascular Anesthesia·Geir O DahleKetil Grong
Sep 10, 1998·Journal of Cardiovascular Pharmacology·R R Ruffolo, G Z Feuerstein
Nov 24, 1999·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·K HvaalS Skjeldal
Aug 3, 2001·Cardiovascular Drug Reviews·J ChengI Kodama

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.